(Credit: Nephron Pharmaceuticals Corporation)
The Nephron Pharmaceuticals Corp. 503B Outsourcing Facility launched a new opioid-free pain management product in response to the current crisis in America. The product, BKK, is a multimodal analgesia containing Bupivacaine, Ketorolac, and Ketamine.
BKK consists of three 20mL prefilled syringes in one pack. Bupivacaine, Ketorolac, and Ketamine are used together as a preventive analgesic to manage post-surgical pain. This opioid sparing product allows for a lower cost of care, diminished risk of readmission, and higher patient safety outcomes, according to Nephron.
“The overuse of opioids has caused an epidemic in our country and too many lives have unnecessarily been lost,” says Lou Kennedy, chief executive officer of Nephron. “Nephron is educating and supplying safer alternatives to surgical intervention with BKK.”
Nephron has partnered with anesthesiologists Dr. W. Bradley Worthington, M.D. of Nashville, TN, and Dr. Richard Teames, M.D. of Fort Worth, TX, to host information sessions across the country regarding opioid-free alternatives.
(Source: Nephron Pharmaceuticals Corp.)
